Price movement over the last 24 hours
ADMA Biologics Inc vs Eaton Corporation plc — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Eaton Corporation plc trades at $399.21 (market cap $153.64B). The key difference: Eaton Corporation plc is far larger — about 72.1× ADMA Biologics Inc's market cap, and Eaton Corporation plc pays a 1.11% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | ETN | |
|---|---|---|
Market Cap | $2.13B | $153.64B |
Sector | Health | Technology |
52-Week High | $20.38 | $435.78 |
52-Week Low | $7.60 | $315.82 |
Enterprise Value | $2.20B | $174.72B |
Dividend Yield | — | 1.11% |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Eaton (ETN) trades at $413.42, up 3.74% with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 20.87% ROE and 13.99% net margin, though valuation ratios like a 40.45 P/E are elevated. Recent news highlights sustainability investments and AI infrastructure opportunities, while analyst consensus remains strongly positive with a $449.50 price target.
Outlook is supported by earnings momentum and sector tailwinds, but high valuation and competitive pressures pose risks. The absence of sell ratings and institutional bullishness suggest upside potential, though investors should weigh growth against premium multiples in a volatile market environment.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →